Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML

Occurrence of the BCR-ABL[superscript T315I] gatekeeper mutation is among the most pressing challenges in the therapy of chronic myeloid leukemia (CML). Several BCR-ABL inhibitors have multiple targets and pleiotropic effects that could be exploited for their synergistic potential. Testing combinati...

Cur síos iomlán

Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Winter, Georg E, Rix, Uwe, Gleixner, Karoline V, Grebien, Florian, Gridling, Manuela, Breitwieser, Florian P, Bilban, Martin, Colinge, Jacques, Valent, Peter, Bennett, Keiryn L, Superti-Furga, Giulio, Carlson, Scott M., White, Forest M., Muller, Andre C
Rannpháirtithe: Massachusetts Institute of Technology. Department of Biological Engineering
Formáid: Alt
Teanga:en_US
Foilsithe / Cruthaithe: Nature Publishing Group 2014
Rochtain ar líne:http://hdl.handle.net/1721.1/89043
https://orcid.org/0000-0002-1545-1651

Ar líne

http://hdl.handle.net/1721.1/89043
https://orcid.org/0000-0002-1545-1651

Míreanna comhchosúla